NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

NOVN.CH

119.52

+0.02%↑

Home・Akcijų sąrašas・Roche Holding AG

Roche Holding AG

Atidarymo kaina

SektoriusSveikatos priežiūra

338 -0.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

337.8

Max

341.4

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.8B 5.5B
Pardavimai	15B 31B
P/E Sektoriaus vid.	21.01 49.701
Dividendų pajamingumas	2.98
Pelno marža	17.892
Darbuotojai	103,249
EBITDA	5.1B 12B

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.98% 2.39%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-21B 268B
Ankstesnė atidarymo kaina	338.35
Ankstesnė uždarymo kaina	338

Naujienos nuotaikos

By Acuity

27%

73%

65 / 345 reitingas Healthcare

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 06:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools

2026-04-23 07:46; UTC

Uždarbis

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

2026-04-23 05:40; UTC

Uždarbis

Roche Backs Full-Year View as Quarterly Sales Rise

2026-03-09 16:43; UTC

Pagrindinės rinkos jėgos

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

2026-03-09 15:44; UTC

Pagrindinės rinkos jėgos

Correction to Roche Shares Article

2026-03-09 09:51; UTC

Pagrindinės rinkos jėgos

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

2026-03-06 09:24; UTC

Pagrindinės rinkos jėgos

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

2026-05-13 10:20; UTC

Rinkos pokalbiai

Uždarbis

Roche Strikes Upbeat Tone on Long-Term Outlook -- Market Talk

2026-05-07 05:53; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Roche to Buy PathAI for up to $1.05B

2026-05-07 05:07; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Acquisition Expected to Complete in 2H

2026-05-07 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche: Closing of Deal Subject to Customary Closing Conditions

2026-05-07 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Pay $750M Upfront, Milestone Payments of Up to $300M

2026-05-07 05:06; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy PathAI for up to $1.5B

2026-05-07 05:05; UTC

Įsigijimai, susijungimai, perėmimai

Roche to Buy PathAI

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-04-27 09:54; UTC

Rinkos pokalbiai

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

2026-04-23 08:10; UTC

Rinkos pokalbiai

Uždarbis

Roche Reports In Line Sales Figures -- Market Talk

2026-04-23 05:04; UTC

Uždarbis

Roche Backs 2026 View

2026-04-23 05:04; UTC

Uždarbis

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

2026-04-23 05:03; UTC

Uždarbis

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

2026-04-23 05:02; UTC

Uždarbis

Roche 1Q Group Sales Up 6% at Constant Currency

2026-04-23 05:02; UTC

Uždarbis

Analysts Saw Roche 1Q Sales at CHF14.73B

2026-04-23 05:01; UTC

Uždarbis

Roche 1Q Sales CHF14.72B

2026-04-10 11:28; UTC

Rinkos pokalbiai

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

2026-04-10 11:17; UTC

Rinkos pokalbiai

Roche to Face Significant Currency Headwinds -- Market Talk

2026-03-11 10:57; UTC

Rinkos pokalbiai

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

2026-03-09 09:43; UTC

Karštos akcijos

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026-03-06 07:22; UTC

Rinkos pokalbiai

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

2026-03-03 07:22; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2026-03-02 14:21; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

Akcijų palyginimas

Kainos pokytis

Roche Holding AG Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Roche Holding AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

65 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Kitos sektoriaus akcijos

NOVN.CH

Novartis AG

119.52

↑ +0.02%

Roche Holding AG

Apžvalga

Akcijų kainos pasikeitimas

Pagrindiniai rodikliai

Dividendai

Rinkos statistika

Naujienos nuotaikos

Roche Holding AG Grafikas

Susijusios naujienos

Akcijų palyginimas

Roche Holding AG Prognozė

Bendras įvertinimas

Rinkos nuotaikos

Finansinės naujienos

Apie bendrovę Roche Holding AG

Kitos sektoriaus akcijos